LRG1 Antibodies

Santa Cruz Biotechnology features a diverse variety of LRG1 monoclonal antibodies for investigating leucine-rich alpha-2-glycoprotein 1 (LRG1) in research applications. LRG1 monoclonal antibodies are validated for multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). LRG1 is a glycoprotein that plays a significant role in inflammation and tissue repair, and has been implicated in various diseases, including cancer and cardiovascular disorders. Expression levels of LRG1 can serve as a biomarker for disease progression and response to therapy, making it an important target for research. Understanding the function of LRG1 can provide insights into the underlying mechanisms of these conditions and aid in the development of therapeutic strategies. Researchers can utilize LRG1 monoclonal antibodies to explore cellular pathways and molecular interactions involved in disease processes. Investigating LRG1 expression patterns helps reveal its role in different physiological and pathological conditions. Santa Cruz Biotechnology monoclonal antibodies for LRG1 support researchers worldwide in advancing scientific understanding of disease mechanisms and potential therapeutic approaches.